Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Budde, Klemens; Becker, Thomas; Arns, Wolfgang; Sommerer, Claudia; Reinke, Petra; Eisenberger, Ute; Kramer, Stefan; Fischer, Wolfgang; Gschaidmeier, Harald; Pietruck, Frank; ZEUS Study Investigators, (2011). Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, 377(9768), pp. 837-47. London: Elsevier 10.1016/S0140-6736(10)62318-5

Full text not available from this repository.

Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension
UniBE Contributor:	Eisenberger, Ute
ISSN:	0140-6736
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:25
Last Modified:	05 Dec 2022 14:07
Publisher DOI:	10.1016/S0140-6736(10)62318-5
PubMed ID:	21334736
Web of Science ID:	000288628500031
URI:	https://boris.unibe.ch/id/eprint/8977 (FactScience: 214637)